Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Coveñas

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
International Journal of Molecular Sciences|March 13, 2024
Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics"Rafael Coveñas
International Journal of Molecular Sciences|November 9, 2024
Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: 2nd Edition"Rafael Coveñas
International Journal of Molecular Sciences|December 11, 2025
Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Third Edition"Rafael Coveñas
Histology and Histopathology|February 19, 2014
Cancer progression and substance PRafael Coveñas, Miguel Muñoz
Expert Opinion on Therapeutic Patents|May 14, 2020
Neurokinin receptor antagonism: a patent review (2014-present)Miguel Muñoz, Rafael Coveñas
Journal of Clinical Medicine|June 5, 2020
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid LeukemiaMiguel Muñoz, Rafael Coveñas
Expert Opinion on Drug Safety|May 28, 2013
Safety of neurokinin-1 receptor antagonistsMiguel Muñoz, Rafael Coveñas
Anti-Cancer Agents in Medicinal Chemistry|April 26, 2018
Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic ApproachMiguel Muñoz, Rafael Coveñas
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|August 5, 2016
Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approachMiguel Muñoz, Rafael Coveñas
Peptides|August 13, 2013
Involvement of substance P and the NK-1 receptor in cancer progressionMiguel Muñoz, Rafael Coveñas
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
International Journal of Molecular Sciences|March 13, 2024
Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics"Rafael Coveñas
International Journal of Molecular Sciences|November 9, 2024
Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: 2nd Edition"Rafael Coveñas
International Journal of Molecular Sciences|December 11, 2025
Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Third Edition"Rafael Coveñas
Histology and Histopathology|February 19, 2014
Cancer progression and substance PRafael Coveñas, Miguel Muñoz
Expert Opinion on Therapeutic Patents|May 14, 2020
Neurokinin receptor antagonism: a patent review (2014-present)Miguel Muñoz, Rafael Coveñas
Journal of Clinical Medicine|June 5, 2020
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid LeukemiaMiguel Muñoz, Rafael Coveñas
Expert Opinion on Drug Safety|May 28, 2013
Safety of neurokinin-1 receptor antagonistsMiguel Muñoz, Rafael Coveñas
Anti-Cancer Agents in Medicinal Chemistry|April 26, 2018
Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic ApproachMiguel Muñoz, Rafael Coveñas
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|August 5, 2016
Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approachMiguel Muñoz, Rafael Coveñas
Peptides|August 13, 2013
Involvement of substance P and the NK-1 receptor in cancer progressionMiguel Muñoz, Rafael Coveñas
Pageof 12